CAL
ALXN

Capital Analysts LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Analysts LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-650
Closed -$74K – 831
2020
Q3 		$74K Sell
650
-650
-50% -$70.1K 0.01% 354
2020
Q2 		$146K Sell
1,300
-1,274
-49% -$135K 0.02% 244
2020
Q1 		$231K Buy
2,574
+600
+30% +$58.9K 0.03% 198
2019
Q4 		$213K Hold
1,974
– – 0.02% 232
2019
Q3 		$193K Buy
1,974
+57
+3% +$6.42K 0.02% 225
2019
Q2 		$251K Buy
1,917
+148
+8% +$19.1K 0.03% 206
2019
Q1 		$239K Hold
1,769
– – 0.03% 205
2018
Q4 		$172K Hold
1,769
– – 0.02% 209
2018
Q3 		$246K Hold
1,769
– – 0.03% 183
2018
Q2 		$220K Hold
1,769
– – 0.03% 191
2018
Q1 		$197K Buy
+1,769
New +$211K 0.02% 188

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return